- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05869708
PRISM Neurofeedback Training for MDD Anhedonic Patients
Personalizing Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia Using Clinical Biomarkers for MDD Subtypes
The goal of this interventional double-blind study is to demonstrate the safety and efficacy of PRISM neurofeedback training within an MDD Anhedonia sample.
The main questions it aims to answer are:
- what clinical profile / symptoms-based biomarkers scores can be used by clinics to administer PRISM therapy in conjunction with standard care of therapy?
- What are the initial guidelines for integrating PRISM neurofeedback training for MDD therapy with MDD Anhedonia?
Participants will be randomly assigned to one of two arms, Active, or Sham.
During the study, participants will perform the following:
- Complete clinical assessments using questionnaires, an MRI scan, and tasks that probe reward responsivity, learning, and motivation.
- Perform 15 (+/-3) neurofeedback training sessions (performed twice a week on nonconsecutive days for about 2 months).
- Complete the same clinical assessments, post-NF training MRI scan, and tasks same as in the screening/baseline stage.
Researchers will compare the sham and treatment arm to evaluate if the neurofeedback effect reduced MDD symptoms in MDD patients with Anhedonia.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Liora Levi, PhD
- Phone Number: +972509260334
- Email: liora@graymatters.health
Study Contact Backup
- Name: Adar Shani
- Phone Number: +972542347770
- Email: adar@graymatters.health
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Recruiting
- McLean Hospital
-
Sub-Investigator:
- Kerry J Ressler, MD
-
Sub-Investigator:
- Isabelle M Rosso, PhD
-
Contact:
- Molly Sapperstein
- Phone Number: 617-855-2247
- Email: neurofeedbackstudy@mclean.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages 22 to 65
- Any gender and all ethnic/racial origins
- Diagnosis of MDD with Anhedonia, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5), with HDRS-21 ≥17 and SHAPS- score ≥25. MDD diagnosis will be determined via the Neuropsychiatric Interview (SCID-V for DSM-5).
- Fall within parameters as defined in the Retrospective stage, and/or anhedonic subtype of MDD
- Right-handed (Chapman and Chapman 1987)
- Fluency in written and spoken English
- Ability to give signed, informed consent either written or electronic (via REDCap eConsent)
- Normal or corrected-to-normal vision and hearing
- Ability to adhere to the study schedule
Exclusion Criteria:
- A history of schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder.
- Lifetime diagnosis of autism or intellectual disability at discretion of investigator.
- Diagnosis of moderate or severe substance use disorder within the last 3 months of screening visit (as defined in DSM-5-substance use disorder) or at screening visit.
- Any prescribed Benzodiazepine which cannot be ceased for the duration of the study (with a washout period of at least 2 weeks prior to the first Prism training session) or which cannot be replaced with short-acting benzodiazepines that are taken only for sleeping during the night at equivalent daily dose of up to 3 mg.
- Current diagnosis of posttraumatic stress disorder (PTSD).
- Any psychotropic medication other than a stable dose of antidepressants, e.g., selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs).
- Because of the focus on RS, any past or current use of DA (Dopamine Agonist)-acting drugs (e.g., bupropion, stimulants, low doses of anti-psychotics used as an augmentation strategy). Also, exclude metformin or any other compound with DA effects.
- Any change in - or initiation of - SSRIs or SNRIs antidepressants within the past 4 weeks. At the time of recruitment, patients must have no intention of changing their medication or psychotherapy (see also exclusion #10) during the study duration.
- Any suicidal behavior in the past 1 year (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) prior to screening and during the screening period.
- Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based MDD psychotherapy (Cognitive Behavior Therapy [CBT], Behavioral Activation Therapy, etc.); continuation of established maintenance supportive therapy will be permitted.
- A history of seizures, at risk for seizure (e.g., history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes or familial or personal history of epilepsy) or have been diagnosed with a seizure disorder.
- Any unstable medical condition, as per the clinical judgment of the investigator.
- Enrollment in another therapeutic clinical study at screening or within 2 months prior to screening, or intended enrollment within the duration of this study.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
- Contraindications to MRI (e.g., metal in body, claustrophobia).
- Hairstyles that prevent the application of the EEG net (e.g., braids, dreadlocks, corn rows, recently dyed hair)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Arm
Subjects randomized into the Active arm will receive RS-EFP-NF Prism training as an adjunct to standard of care.
|
15 (+/- 3) active NF Prism training sessions, aimed to train for upregulating the RS activity.
Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks.
Subjects will also receive two single booster sessions, one month and two months after their last training session.
|
Sham Comparator: Control Arm
Subjects randomized into the Control arm will receive a Sham-EFP-NF training with the same schedule as the active arm, adjunct to standard of care.
|
15 (+/- 3) sham NF Prism training sessions, aimed to train for upregulating the RS activity.
Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks.
Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HDRS-21
Time Frame: 9 weeks
|
The HDRS (also known as the Ham-D) is the most widely used clinician-administered depression assessment scale.
It is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
Each item on the questionnaire is scored on a 3- or 5-point scale, depending on the item, and the total score is compared to the corresponding descriptor.
Assessment time is about 20 minutes.
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Snaith Hamilton Pleasure Scale - self reported (SHAPS-SR)
Time Frame: 9 weeks
|
The Snaith Hamilton Pleasure Scale (Snaith et al., 1995) is a 14- item self-administered measure of anhedonic symptoms.
The purpose of this assessment is to evaluate the ability to enjoy/experience pleasure in activities in the past week.
Each item is rated on a 4-point Likert scale, where the total score ranges between 0 to 42 and a higher total score means a worse outcome.
|
9 weeks
|
HDRS-21
Time Frame: 3 months
|
The HDRS (also known as the Ham-D) is the most widely used clinician-administered depression assessment scale.
It is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
Each item on the questionnaire is scored on a 3- or 5-point scale, depending on the item, and the total score is compared to the corresponding descriptor.
Assessment time is about 20 minutes.
|
3 months
|
Snaith Hamilton Pleasure Scale - self reported (SHAPS-SR)
Time Frame: 3 months
|
The Snaith Hamilton Pleasure Scale (Snaith et al., 1995) is a 14- item self-administered measure of anhedonic symptoms.
The purpose of this assessment is to evaluate the ability to enjoy/experience pleasure in activities in the past week.
Each item is rated on a 4-point Likert scale, where the total score ranges between 0 to 42 and a higher total score means a worse outcome.
|
3 months
|
The clinical global impression (CGI-I)
Time Frame: 9 weeks
|
The CGI-I Scale - of Clinical Global Impression (Guy et.al, 1976) - is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
Rated within the range of 0 to 7, lower scores indicate improved outcomes while higher scores indicate worsen outcomes.
|
9 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Diego Pizzagalli, PhD, McLean Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Active RS-EFP
-
Bowen Chung, MD, MSHSTulane University; University of California, San Francisco; Louisiana State University... and other collaboratorsUnknownDepressive SymptomsUnited States
-
NYU Langone HealthCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownStress Disorders, Post-Traumatic | Feedback, PsychologicalIsrael
-
Tel-Aviv Sourasky Medical CenterTel Aviv UniversityUnknown
-
Southern Illinois University EdwardsvilleTerminatedMenstrual Cycle | Substrate MetabolismUnited States
-
Southern Illinois University EdwardsvilleTerminatedBody Image DisturbanceUnited States
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Binding Sciences LimitedBuckinghamshire Healthcare NHS TrustNot yet recruiting
-
NovavaxCompleted
-
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret...Recruiting